Showing results (151-160 of 278) with videos related to
Sort By:
Pageof 28
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJohn A Thompson, Omid Hamid, David Minor, et al.The New England Journal of Medicine|June 21, 2008
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1Naomi N Hunder, Herschel Wallen, Jianhong Cao, et al.Head & Neck|July 16, 2013
Fast neutron radiotherapy for primary mucosal melanomas of the head and neckJay J Liao, Upendra Parvathaneni, George E Laramore, et al.Journal for Immunotherapy of Cancer|January 13, 2021
Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitisFangwen Zou, Xuemei Wang, Isabella C Glitza Oliva, et al.Operative Neurosurgery (Hagerstown, Md.)|December 19, 2017
Ophthalmic Complications Following Acoustic Neuroma ResectionWilliam S Gange, Ian D Kirchner, John A Thompson, et al.Neuromodulation : Journal of the International Neuromodulation Society|February 6, 2020
Striatal and Thalamic Auditory Response During Deep Brain Stimulation for Essential Tremor: Implications for PsychosisJudith M Gault, John A Thompson, Keeran Maharajh, et al.Journal for Immunotherapy of Cancer|September 2, 2018
Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case reportJacob Appelbaum, David Wells, Joseph B Hiatt, et al.Acta Neurochirurgica|May 19, 2023
Surgical outcomes in large vestibular schwannomas: should cerebellopontine edema be considered in the grading systems?Timothy H Ung, Lindsey Freeman, Lisa Hirt, et al.AJNR. American Journal of Neuroradiology|August 14, 2025
Delineation of the Centromedian Nucleus for Epilepsy Neuromodulation Using Deep Learning Reconstruction of White Matter-Nulled ImagingMegan V Ryan, David Satzer, Houchun Hu, et al.Investigational New Drugs|December 28, 2005
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis, John A Thompson, Jeffrey S Weber, et al.Pageof 28